All In Biotech

Drug Trial Radar · NCT06142188

Relmacabtagene Autoleucel in Hematologic Malignancies

A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel

Last checked: Nov 19, 2026Latest source record: Nov 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Dec 28, 2023

Primary completion

Dec 31, 2038

Study completion Dec 31, 2038

Sponsor

Sponsor type
Industry
First posted
Nov 21, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world

Conditions

  • Lymphoma, B-Cell
  • Large B-cell Lymphoma
  • Follicular Lymphoma

Interventions

  • Relmacabtagene AutoleucelBiological

    A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: 15 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Peking University International Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.